Is Takeda Pharmaceutical Company Limited a good dividend stock?

Takeda Pharmaceutical Company Limited (TAK) is a dividend-paying stock with a current dividend yield of 3.88%. Review its dividend history, payout consistency and growth to judge whether it fits your income strategy.

What is TAK's dividend yield?

The dividend yield for TAK stock is currently 3.88%.

How much does TAK pay in dividends per year?

Takeda Pharmaceutical Company Limited pays an annual dividend of $0.6206 per share over the trailing twelve months.

How often does TAK pay dividends?

TAK stock pays dividends bi-annually.

Is TAK's dividend growing?

Takeda Pharmaceutical Company Limited's 3-year dividend CAGR is 10.77%.

TAK Stock Price, Chart, Stats & News

Takeda Pharmaceutical Company Limited

Save

Overview Dividend safety Dividends Fundamentals

Takeda Pharmaceutical Company Limited (TAK) is a dividend-paying stock with a current dividend yield of 3.88% as of Jun 29, 2026. It pays $0.6206 per share over the trailing twelve months and distributes bi-annually. Its dividend has grown at a 1.08% 5-year compound annual rate.

50.49B

Market cap

9.29x

Current P/E

10.29x

Forward P/E

3.88%

Dividend yield

$0.6206

TAK dividend

Dividend safety

Strong

Dividend coverage looks healthy — TAK pays out about 36% of earnings.

See the safety analysis

TAK chart

Loading chart...

Fundamentals

Gross margin	62.11%
Operating margin	8.31%
Pretax margin	4.63%
Net margin	2.56%
Effective tax rate	44.63%
ROA	0.74%
ROE	1.61%
D/E	0.64x
Interest coverage ratio	1.18x

All financials

TAK valuation

P/E	9.29x
P/S	2.02x
P/B	1.19x
P/CF	7.71x
P/FCF	9.48x
P/OCF	7.71x
PEG	0.00x
EV multiple	3.49x

About

Health care

Sector

Drug Manufacturers - Specialty & Generic

Industry

Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions.